Report covers peptide receptor radionuclide therapy after liver transplant
The paper addresses recurrent neuroendocrine tumors treated with PRRT in patients who have already undergone liver transplantation.
PR
By Priya Raman · Science Reporter
Oct 14 22:19 ETSource: Baishideng Publishing Group
The wire
- 01Baishideng Publishing Group published a report on peptide receptor radionuclide therapy for neuroendocrine tumors that recurred after liver transplantation.
- 02PRRT uses radiolabeled somatostatin analogs, so oncology and pharmacy readers tracking approved peptide drugs will want the full text for dosing and safety context.
- 03Only the title is available; the patient numbers, isotope, regimen and outcomes are not stated here.
From the source
Read at wjgnet.comPeptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation
